- Home
- UNCY vs ELEV Comparison
UNCY vs ELEV Comparison
Compare UNCY & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- ELEV
- Stock Information
- Founded
- UNCY 2016
- ELEV 2019
- Country
- UNCY United States
- ELEV United States
- Employees
- UNCY N/A
- ELEV N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- ELEV Health Care
- Exchange
- UNCY Nasdaq
- ELEV Nasdaq
- Market Cap
- UNCY 91.0M
- ELEV 22.6M
- IPO Year
- UNCY 2021
- ELEV 2021
- Fundamental
- Price
- UNCY $4.95
- ELEV $0.38
- Analyst Decision
- UNCY Strong Buy
- ELEV Hold
- Analyst Count
- UNCY 4
- ELEV 6
- Target Price
- UNCY $63.75
- ELEV $1.77
- AVG Volume (30 Days)
- UNCY 1.2M
- ELEV 938.5K
- Earning Date
- UNCY 08-13-2025
- ELEV 08-05-2025
- Dividend Yield
- UNCY N/A
- ELEV N/A
- EPS Growth
- UNCY N/A
- ELEV N/A
- EPS
- UNCY N/A
- ELEV N/A
- Revenue
- UNCY N/A
- ELEV N/A
- Revenue This Year
- UNCY N/A
- ELEV N/A
- Revenue Next Year
- UNCY $1,458.53
- ELEV N/A
- P/E Ratio
- UNCY N/A
- ELEV N/A
- Revenue Growth
- UNCY N/A
- ELEV N/A
- 52 Week Low
- UNCY $2.02
- ELEV $0.22
- 52 Week High
- UNCY $11.00
- ELEV $3.28
- Technical
- Relative Strength Index (RSI)
- UNCY 43.02
- ELEV 54.73
- Support Level
- UNCY $4.31
- ELEV $0.36
- Resistance Level
- UNCY $5.55
- ELEV $0.38
- Average True Range (ATR)
- UNCY 0.76
- ELEV 0.01
- MACD
- UNCY -0.10
- ELEV -0.00
- Stochastic Oscillator
- UNCY 16.26
- ELEV 53.93
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.